A TCR-based bispecific T-cell engager that binds the MAGE-A4 peptide presented by HLA-A*02 on tumor cells and CD3 on T cells to redirect and activate cytotoxic T cells.
TCR-based bispecific that binds the MAGE-A4 peptide presented by HLA-A*02 on tumor cells and CD3 on T cells, redirecting and activating polyclonal cytotoxic T cells to induce tumor cell lysis.
YES
DIRECT
TCR-based bispecific bridges CD3 on T cells to the MAGE-A4/HLA-A*02 pHLA on target cells, forming an immune synapse and activating cytotoxic T cells to kill via perforin/granzyme (and Fas–FasL)–mediated apoptosis.
Anti-EGFR IgG1 monoclonal antibody that blocks EGFR signaling (RAS/MAPK, PI3K/AKT) and can mediate ADCC against EGFR-expressing tumor cells.
Humanized IgG1 monoclonal antibody against EGFR that blocks ligand binding and downstream EGFR signaling (RAS/MAPK and PI3K/AKT), inhibiting proliferation and survival of EGFR-overexpressing tumor cells; its Fc region can mediate antibody-dependent cellular cytotoxicity (ADCC).
YES
DIRECT
IgG1 anti-EGFR mAb engages FcγR-bearing effector cells to kill EGFR+ cells via ADCC (and possibly CDC); EGFR signaling blockade is antiproliferative.
A TCR-based bispecific T-cell engager that binds the MAGE-A4 peptide presented by HLA-A*02 on tumor cells and CD3 on T cells to redirect and activate cytotoxic T cells.
TCR-based bispecific that binds the MAGE-A4 peptide presented by HLA-A*02 on tumor cells and CD3 on T cells, redirecting and activating polyclonal cytotoxic T cells to induce tumor cell lysis.
NO
INDIRECT
The bispecific binds CD3 on T cells and MAGE-A4/HLA-A*02 on tumor cells, activating T cells to kill the tumor via perforin/granzyme-mediated cytolysis; CD3+ T cells are not killed.
Autologous, gene-engineered TCR-T cell therapy expressing an HLA-A*02:01–restricted TCR specific for the TP53 R175H mutant peptide to mediate antigen-specific tumor cell killing.
Autologous T cells are gene-engineered to express an HLA-A*02:01–restricted T-cell receptor that recognizes the TP53 R175H mutant peptide presented on tumor MHC class I. After infusion, these TCR-T cells bind the peptide–MHC complex, become activated, and kill antigen-positive tumor cells via cytotoxic effector functions (perforin/granzymes and cytokines).
YES
DIRECT
Engineered TCR-T cells bind the HLA-A*02:01–presented TP53 R175H peptide on tumor cells and kill them via cytotoxic T-cell effector functions (perforin/granzyme-mediated apoptosis, etc.).
Autologous, gene-engineered TCR-T cell therapy expressing an HLA-A*02:01–restricted TCR specific for the TP53 R175H mutant peptide to mediate antigen-specific tumor cell killing.
Autologous T cells are gene-engineered to express an HLA-A*02:01–restricted T-cell receptor that recognizes the TP53 R175H mutant peptide presented on tumor MHC class I. After infusion, these TCR-T cells bind the peptide–MHC complex, become activated, and kill antigen-positive tumor cells via cytotoxic effector functions (perforin/granzymes and cytokines).
YES
DIRECT
Engineered TCR-T cells recognize the HLA-A*02:01–TP53 R175H peptide complex, become activated, and kill the antigen-positive cells via perforin/granzyme-mediated cytolysis (and related CTL effector mechanisms).